Treatment of Meniere's Disease With Migraine Medications

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Oct 12, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating the use of migraine medications to treat Meniere's disease, a condition that causes troubling symptoms like vertigo (a spinning sensation), hearing loss, ringing in the ears, and feelings of fullness in the ear. These symptoms can be very distressing and affect daily life significantly. Since there are currently no approved medications specifically for Meniere's disease, this study aims to explore the effectiveness of these migraine treatments based on promising results seen in earlier practices.

To participate in this study, individuals must be between 25 and 85 years old and have frequent symptoms of Meniere's disease. Participants need to be able to understand and sign consent forms in English and should be willing to follow the treatment plan and attend study visits. However, individuals who are pregnant, have had surgery for Meniere's disease, or have certain medical conditions may not be eligible to join. Those who take part can expect to receive one of the migraine medications and will be closely monitored throughout the trial to see how well it helps their Meniere's symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with active or frequent Meniere's Disease.
• • 2. Male or female between the ages of 25 to 85 years.
• • 3. Subject must be compliant with the medication and attend study visits.
• • 4. Must be able to read and write in the English language to provide consenting.
• Exclusion Criteria:
• • 1. Pregnancy will result in automatic exclusion from the study. A urine pregnancy test to rule out pregnancy for all women who are of childbearing potential.
• • 2. Subjects with history of surgery for Meniere's Disease.
• • 3. Subject with history of an adverse reaction to medication being prescribed.
• • 4. Subject suffers from a medical condition or has history that may be concerning to the investigator's clinical opinion.
• • 5. Subjects with psychosis.
• • 6. Subjects with neurological neoplasm.
• • 7. All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria.